Can I read Efficacy of Olverembatinib in Ph+ ALL on EtoBox?
Efficacy of Olverembatinib in Ph+ ALL by Hugo Hector is a document available to read on EtoBox.
What is Efficacy of Olverembatinib in Ph+ ALL about?
The commentary discusses the potential of olverembatinib, a new third-generation tyrosine kinase inhibitor (TKI), in treating Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL), particularly in patients with the T315I mutation. A retrospective study indicated that olverembatinib combined with chemotherapy achieved a complete remission rate of 71.4% in relapsed/refractory cases, suggesting it could serve as a viable treatment option and bridge to stem cell transplantation. Future clinical tr
- Author
- Hugo Hector
- Language
- EN